Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| NYU Langone's Perlmutter Cancer Center Earns Redesignation as a Comprehensive Cancer Center from the National Cancer Institute | ||
| By: PR Newswire Association LLC. - 18 Apr 2024 | Back to overview list |
|
|
NEW YORK, April 18, 2024 /PRNewswire/ -- NYU Langone Health's Laura and Isaac Perlmutter Cancer Center has once again been designated as a Comprehensive Cancer Center, the highest ranking awarded by the National Cancer Institute and further validation that it provides state-of-the-art, research-based approaches to preventing, detecting, and treating cancer. Perlmutter Cancer Center is among only 56 institutions recognized across the nation for earning this elite distinction. This comes with a competing renewal of its Cancer Center Support Grant (CCSG), which will provide nearly $20 million over five years in new funding for research programs, infrastructure, and technology.
Perlmutter Cancer Center achieved its ranking by demonstrating success in the following areas:
In the years since receiving comprehensive designation in 2019, Perlmutter Cancer Center has continued to expand, with more than 39 sites across Manhattan, Brooklyn, Queens and Long Island. "Our expanded footprint allows us to serve one of the largest, most diverse populations in the nation and to provide extensive community outreach to offer patients the most advanced cancer care near where they live ," said Alec Kimmelman, MD, PhD, director of Perlmutter Cancer Center, and the Anita Steckler and Joseph Steckler chair of the Department of Radiation Oncology. "This redesignation affirms our accomplishments in cancer research, clinical trials, as well as many other cancer prevention and control initiatives." "Perlmutter Cancer Center continues to attract exceptional oncologists who recognize the unique and exciting opportunities that exist here to revolutionize the way we treat cancer," said Robert I. Grossman, MD, Dean and CEO of NYU Langone Health. "I have no doubt that, under Alec's leadership, we will continue to elevate the compassionate and world-class care that we offer across NYU Langone." Research and Clinical Care Excellence Recent research highlights include the Melanoma SPORE (NCI P50 Specialized Programs of Research Excellence), an $11 million grant to develop tools that predict which patients with advanced melanoma will benefit from immune checkpoint inhibitors. In addition, faculty continue to make breakthroughs in diagnosis and treatment for various cancers, such as combining chemoradiation with immunotherapy for muscle-invasive bladder cancer, new treatments for non-small cell lung cancer, using personalized mRNA vaccines for melanoma, and an antibody-drug conjugate in women with metastatic breast cancer. Over the past five years, Perlmutter Cancer Center has tripled the size of its clinical trials office, nearly doubled its trial accrual, and doubled its phase I trial portfolio. It has also has continued to develop clinical programs to meet our patients' needs. The Blood and Marrow Transplant Program received certification from the Foundation for the Accreditation of Cellular Therapy (FACT) to perform adult allogeneic transplant, expanding its services, and also opened up a physical location. Experts at Perlmutter Cancer Center have also implemented screening approaches to diagnose lung cancer in non-smokers. Media Inquiries
SOURCE NYU Langone Health 
|
||
|
||
 | Back to overview list | |
View original content to download multimedia: